At a Glance
- Company: Fortress Biotech
- Location: New York, USA
- Deal value: Approximately $205 million
- Focus area: Paediatric rare disease drug Zycubo (orphan approval)
- Next steps: Deploy proceeds into clinical pipeline and operations
What happened?
Fortress Biotech sold a rare paediatric priority review voucher (PRV) earned from the FDA approval of Zycubo, its orphan drug for a paediatric rare disease, for about $205 million in cash. The transaction closed shortly after approval, allowing Fortress to immediately monetise the valuable regulatory asset. PRVs grant six-month priority FDA review and are tradable, often fetching high premiums from big pharma.
Why does it matter?
PRVs provide critical non-dilutive funding for cash-strapped biotechs; this $205M windfall bolsters Fortress’s balance sheet amid ongoing pipeline investments. Zycubo’s approval validates Fortress’s rare disease strategy, while the sale underscores PRVs’ role in bridging commercialisation gaps for orphan products without equity dilution.
Who’s behind it?
Fortress Biotech, a New York-based revenue-generating company, develops and partners therapies across oncology, diagnostics and rare diseases. Buyer details undisclosed, but PRVs typically go to majors like Pfizer or Novartis seeking accelerated launches.
How was it achieved?
Zycubo earned PRV eligibility via FDA paediatric rare disease designation and approval pathway. Fortress marketed the voucher post-approval through specialised intermediaries, securing a buyer at a premium valuation reflecting strong market demand for review acceleration amid packed FDA queues.
What’s next?
Proceeds will fund Fortress’s diverse pipeline, including late-stage assets in oncology and rare diseases, while extending cash runway. No impact on Zycubo commercialisation; company eyes additional PRV opportunities from orphan portfolio.